Dermatitis Herpetiformis

Dermatitis herpetiformis (DH) is an intensely itchy, chronic blistering skin disease caused by gluten sensitivity — the same immune mechanism that drives celiac disease. Although it presents on the skin, it is fundamentally a systemic autoimmune condition in which ingested gluten triggers IgA antibody deposits in the dermis, igniting blisters on the elbows, knees, buttocks, and scalp. A strict gluten-free diet is both the primary treatment and the only therapy that addresses the underlying disease rather than masking its symptoms.

Table of Contents

1. What Is Dermatitis Herpetiformis?
2. Pathophysiology: The Gluten-IgA Connection
3. Epidemiology and Risk Factors
4. Clinical Features and Symptoms
5. Diagnostic Approach
6. Treatment: Gluten-Free Diet and Dapsone
7. Monitoring and Long-Term Management
8. Key Research Papers
9. Related PubMed Searches
10. Featured Videos
11. Connections

What Is Dermatitis Herpetiformis?

Dermatitis herpetiformis is the pathognomonic cutaneous manifestation of celiac disease — the skin expression of gluten-sensitive enteropathy. First described by Louis Duhring in 1884, it was long considered a purely dermatological condition until the 1960s and 1970s, when researchers established its inseparable connection to intestinal gluten intolerance and small bowel villous atrophy.

Despite its name, DH has no relationship to herpes viruses. The term "herpetiformis" refers only to the appearance of grouped (herpetiform) vesicles, which mimic the cluster pattern of herpesvirus skin lesions. The cause is entirely immunological, driven by gluten consumption in genetically susceptible individuals.

DH is classified as an autoimmune bullous (blistering) dermatosis. Unlike many other blistering diseases that affect the skin in isolation, DH reflects systemic gluten intolerance — meaning most patients have concurrent intestinal damage even when they have no digestive symptoms whatsoever. Treating only the skin without addressing the diet leaves the underlying celiac disease active and the patient at continued risk for long-term complications.

Back to Table of Contents

Pathophysiology: The Gluten-IgA Connection

The mechanism linking dietary gluten to skin blistering involves a multi-step autoimmune cascade that operates across both the gut and the skin simultaneously.

Step 1 — Gluten sensitization: In genetically susceptible individuals (those carrying HLA-DQ2 or HLA-DQ8 haplotypes), dietary gluten — specifically the gliadin component of wheat, rye, and barley — is incompletely digested in the small intestine. Tissue transglutaminase 2 (TG2) in the gut wall deamidates gliadin peptides, creating epitopes that are recognized as foreign by antigen-presenting cells bearing HLA-DQ2 or HLA-DQ8.

Step 2 — Dual antibody production: The adaptive immune response generates IgA antibodies against two closely related enzyme targets. Anti-tissue transglutaminase 2 (anti-TG2) antibodies cause intestinal damage — the same antibodies found in classic celiac disease. Critically, the immune response also cross-reacts with epidermal transglutaminase 3 (TG3, eTG), a structurally related enzyme expressed in the skin. Anti-TG3 IgA antibodies are the skin-specific autoantibody of DH and are the most diagnostically specific serum marker for this condition.

Step 3 — Dermal IgA deposition: IgA-TG3 immune complexes circulate in the bloodstream and deposit in the papillary dermis — the uppermost layer of the dermis just beneath the epidermis, where small capillaries and collagen bundles project upward into the epidermal folds (dermal papillae). This deposition occurs at the tips of the dermal papillae and is independent of whether the skin is visibly inflamed.

Step 4 — Complement activation and neutrophil infiltration: The IgA deposits activate complement via the alternative and lectin pathways, generating chemotactic fragments (C3a, C5a) that recruit neutrophils into the papillary dermis. Neutrophil accumulation at papillary tips releases proteolytic enzymes (including elastase and collagenase) that cleave the dermoepidermal junction, producing subepidermal fluid-filled blisters.

Key insight: The skin lesions are driven by the same gluten intake that damages the intestinal mucosa. Gluten elimination depletes the antigenic stimulus, stops new IgA complex formation, and eventually allows existing deposits to clear — explaining why the gluten-free diet is the only true disease-modifying treatment.

Back to Table of Contents

Epidemiology and Risk Factors

DH has a pronounced Northern European predominance, reflecting the distribution of HLA-DQ2 and DQ8 haplotypes. Prevalence in Finland — one of the most studied populations — approaches 1 in 1,000. In the United States the prevalence is estimated at approximately 1 in 10,000, though this likely underestimates true frequency due to underdiagnosis and delayed diagnosis averaging 10 or more years from symptom onset.

Sex distribution: Unlike celiac disease, which is approximately twice as common in women, DH shows roughly equal sex distribution, with some studies suggesting a slight male predominance. The reason for this difference is not fully understood but may relate to sex differences in skin IgA trafficking.

Age of onset: DH can occur at any age but most commonly presents in the third and fourth decades of life. Pediatric DH is recognized but uncommon. Late-onset DH in elderly patients is increasingly reported.

Genetic risk factors:

• HLA-DQ2 (encoded by HLA-DQA1*05 and HLA-DQB1*02): present in approximately 90–95% of DH patients
• HLA-DQ8 (encoded by HLA-DQA1*03 and HLA-DQB1*03:02): accounts for most of the remaining cases
• First-degree relatives of DH patients have significantly elevated risk of both DH and celiac disease

Associated autoimmune conditions: DH clusters with other organ-specific autoimmune diseases, consistent with shared HLA haplotypes and immune dysregulation:

• Thyroid disease: Hashimoto's thyroiditis and Graves' disease — the most common associations, present in 10–15% of DH patients
• Type 1 diabetes mellitus
• Pernicious anemia (autoimmune gastritis with intrinsic factor antibodies)
• Systemic lupus erythematosus (SLE)
• Sjögren's syndrome
• Alopecia areata

Dietary triggers beyond classic gluten: Iodine intake can transiently worsen DH skin disease in some patients, possibly by exacerbating neutrophil recruitment at existing IgA deposits, though iodine restriction is not routinely recommended. Oats represent a nuanced case — most DH patients can tolerate certified gluten-free oats once the disease is well controlled on a gluten-free diet, though a minority have oat-specific sensitivity.

Back to Table of Contents

Clinical Features and Symptoms

The clinical presentation of DH is distinctive but frequently misdiagnosed as eczema, scabies, or insect bites before the correct diagnosis is reached.

Pruritus as the defining symptom: DH produces one of the most intensely pruritic rashes in dermatology. The itch is characteristically described as burning and stinging rather than pure itch, and this burning sensation often precedes the appearance of visible lesions by hours. Patients frequently scratch lesions to the point of excoriation before they present to a physician, meaning intact vesicles are often absent at the time of clinical examination.

Primary lesion morphology: When intact, the primary lesion is a small tense vesicle (blister) arising on an erythematous base, grouped in clusters (hence "herpetiformis"). Papules and urticarial plaques also occur. Because vesicles are rapidly excoriated, the clinician more often sees:

• Erosions — denuded skin where vesicle roofs have been scratched off
• Excoriations — linear scratch marks
• Post-inflammatory hyperpigmentation — brown macules marking healed lesions
• Lichenification — thickened skin from chronic scratching

Distribution: DH has a strikingly symmetric, extensor-predominant distribution:

• Elbows — the single most common site, affected in the vast majority of patients
• Knees — second most common
• Buttocks and sacrum — very characteristic; buttock involvement alone should prompt consideration of DH
• Posterior scalp and hairline
• Shoulders and upper back
• Anterior scalp and neck — less commonly

The face and mucous membranes are rarely involved, distinguishing DH from pemphigus vulgaris. Palms and soles are generally spared.

Gastrointestinal involvement: Approximately 90% of DH patients have villous atrophy on duodenal biopsy — the same finding seen in classic celiac disease. However, only about 20% have overt gastrointestinal symptoms (diarrhea, bloating, abdominal pain). The majority of DH patients have subclinical celiac enteropathy: histological intestinal damage that is silent because the compensatory mucosal surface area of the small intestine masks nutritional deficiency. This fact is clinically important — a DH patient who denies GI symptoms still has active celiac disease and still requires a gluten-free diet.

Nutritional consequences of silent celiac disease: Even without overt GI symptoms, DH patients may present with iron-deficiency anemia (most common), folate deficiency, vitamin B12 deficiency (less common, as terminal ileum is usually spared), osteoporosis, and neurological sequelae.

Back to Table of Contents

Diagnostic Approach

The diagnosis of DH rests on skin biopsy with direct immunofluorescence (DIF). This is the gold-standard test. Serology provides supportive evidence and is useful for monitoring, but cannot substitute for histopathology in establishing the diagnosis.

Skin biopsy — site selection is critical: The biopsy must be taken from perilesional skin — normal-appearing skin immediately adjacent to (within 1 cm of) an active lesion. Biopsy of the lesion itself is diagnostically unreliable: the blister and surrounding intense inflammation obscure the characteristic IgA deposits and produce a nonspecific picture. Perilesional skin, which appears normal to the naked eye, harbors the diagnostic IgA deposits without inflammatory artifact.

Direct immunofluorescence (DIF): The perilesional biopsy is processed in Michel's transport medium (not formalin) and examined by immunofluorescence microscopy. The pathognomonic finding is granular IgA deposits in the dermal papillae. This granular (particulate) IgA staining pattern distinguishes DH from Linear IgA Bullous Dermatosis, which shows a linear band of IgA at the dermoepidermal junction. Fibrin and C3 complement fragments are also commonly seen at papillary tips. IgG and IgM deposits are absent or minimal.

Serology:

• Anti-TG3 IgA (anti-epidermal transglutaminase) — the most specific serum marker for DH; not yet universally available but increasingly offered by reference laboratories
• Anti-TG2 IgA (anti-tissue transglutaminase) — elevated in the majority of DH patients; the same test used to diagnose celiac disease; normalizes with sustained gluten-free diet and is useful for monitoring dietary compliance
• Anti-endomysial IgA (EMA) — highly specific for celiac/DH spectrum; test is expensive and observer-dependent
• Anti-deamidated gliadin peptide (DGP) IgA — useful when total IgA deficiency is suspected (IgA-deficient patients produce IgG class antibodies instead)
• Total serum IgA — measure to rule out IgA deficiency; IgA-deficient patients (prevalence ~1:300) will have false-negative IgA-based serology and require IgG-class antibody testing

Duodenal biopsy: Gastroenterological evaluation with upper endoscopy and duodenal biopsy can demonstrate Marsh grade 2–3 villous atrophy, confirming the celiac enteropathy that underlies DH. Duodenal biopsy is not required for the DH diagnosis when DIF is positive and clinical presentation is consistent, but is often performed to document the extent of intestinal disease and to establish a baseline for monitoring.

Differential diagnosis:

• Linear IgA Bullous Dermatosis — clinically similar but shows linear (not granular) IgA on DIF; often drug-induced (vancomycin, NSAIDs); not gluten-related
• Bullous Pemphigoid — subepidermal blisters but IgG (not IgA) deposits; linear pattern; typically elderly patients
• Pemphigoid Gestationis — pregnancy-associated; linear C3 and IgG
• Scabies — intensely pruritic; burrows; mite/eggs on scraping
• Atopic Dermatitis — flexural distribution, negative DIF, no IgA deposits

Back to Table of Contents

Treatment: Gluten-Free Diet and Dapsone

Management of DH combines a disease-modifying dietary intervention (gluten-free diet) with a symptom-suppressing drug (dapsone) used as a bridge while the diet takes effect.

Gluten-Free Diet (GFD)

The GFD is the primary and definitive treatment for DH. It is the only intervention that addresses both the skin disease and the underlying intestinal celiac damage simultaneously. Key points:

• What to eliminate: All sources of gluten — wheat (including spelt, kamut, durum, semolina, farro), barley, rye, and triticale. Oats must be certified gluten-free due to cross-contamination risk in conventional production.
• Time to skin remission: Unlike dapsone, which works within 48 hours, the GFD requires 1–2 years of strict adherence before the skin disease is fully suppressed. IgA deposits in the dermis clear slowly — DIF IgA deposits may persist for 2 or more years even with perfect dietary compliance.
• Strictness required: The threshold for DH is very low — even traces of gluten (from cross-contamination, shared cooking surfaces, unlabeled additives) can perpetuate disease. A registered dietitian experienced with celiac disease is an essential part of the treatment team.
• Gut healing: Villous atrophy in the duodenum begins recovering within weeks of strict GFD and typically normalizes within 1–2 years in adults (faster in children).
• Dapsone dose reduction: As the GFD takes effect, dapsone requirements typically decline and can often be discontinued after 1–2 years in patients maintaining strict dietary compliance.

Dapsone (Diaminodiphenyl Sulfone)

Dapsone is the primary pharmacological therapy for DH. It produces dramatic symptomatic relief but does not modify the underlying disease:

• Mechanism: Dapsone inhibits neutrophil chemotaxis, reduces neutrophil oxidative burst, and suppresses IgA-mediated complement activation in the skin — suppressing the inflammatory cascade that produces blisters without eliminating the cause (IgA deposits).
• Speed of response: Symptoms typically begin to improve within 24–48 hours of initiating dapsone. This rapid response both provides relief and serves as a quasi-diagnostic test — a dramatic response to dapsone in a patient with the right clinical picture strongly supports the DH diagnosis.
• Dosing: Start at 25–50 mg/day and titrate to the lowest effective dose, typically 25–200 mg/day depending on disease severity. Lower doses suffice as the GFD takes effect.
• Monitoring requirements:
  • G6PD deficiency screen before starting — dapsone causes oxidative hemolysis; G6PD-deficient patients are at high risk of severe hemolytic anemia and dapsone should generally be avoided in this group
  • CBC — monitor for dose-dependent hemolytic anemia (universal, even in G6PD-normal patients at higher doses) and agranulocytosis (rare but serious)
  • Methemoglobin levels — dapsone produces methemoglobin; methemoglobinemia is dose-dependent; treat symptomatic methemoglobinemia with methylene blue 1–2 mg/kg IV
  • Liver function tests — hepatotoxicity occurs rarely
  • Peripheral neuropathy — with long-term high-dose use

Alternative Agents for Dapsone-Intolerant Patients

When dapsone is contraindicated (G6PD deficiency, allergy, intolerance), alternatives include:

• Sulfapyridine — second-line sulfonamide; less effective than dapsone; monitoring for hemolysis and agranulocytosis required
• Colchicine — inhibits neutrophil motility; modest efficacy
• Tetracycline + niacinamide — combination with anti-neutrophil properties; used in patients unable to tolerate sulfonamide drugs

Topical steroids and antihistamines provide minimal relief for the intense itch of DH and are not considered adequate monotherapy.

Back to Table of Contents

Monitoring and Long-Term Management

DH requires lifelong management because the underlying gluten sensitivity does not resolve. With sustained strict dietary adherence, however, most patients achieve complete skin remission and significantly reduce their cancer risk.

Laboratory monitoring:

• Anti-TG2 IgA and/or anti-TG3 IgA — recheck at 6 and 12 months after GFD initiation, then annually. Normalization confirms dietary compliance and predicts eventual skin remission. Persistently elevated antibodies indicate continued gluten exposure, even if the patient believes they are compliant.
• CBC and methemoglobin — every 3–6 months while on dapsone
• Iron studies, folate, B12, vitamin D, bone density (DEXA) — screen at diagnosis and periodically, as malabsorption from subclinical celiac disease may have been ongoing for years

Long-term cancer risk: Untreated or poorly controlled celiac disease — including the subclinical celiac disease of DH — is associated with a modestly elevated risk of intestinal T-cell lymphoma, specifically enteropathy-associated T-cell lymphoma (EATCL). This rare but serious complication arises from chronically activated intraepithelial T lymphocytes in the setting of persistent mucosal inflammation. The absolute risk is low (estimated 5–7 per 100,000 patient-years), but it is meaningfully higher than the general population. Sustained strict gluten-free diet appears to reduce this risk to background levels. Non-responsive or refractory disease warrants gastroenterological evaluation and endoscopic surveillance to assess mucosal healing and exclude lymphoma development.

Pregnancy and DH: DH can worsen, improve, or remain unchanged during pregnancy. The GFD should be maintained throughout pregnancy. Dapsone is classified as FDA category C — it is often continued during pregnancy when benefit outweighs risk, but decisions should involve obstetrics. Neonatal dapsone exposure can cause hemolytic anemia in the newborn; pediatric monitoring is recommended.

Children and adolescents: DH in children requires particularly attentive dietary counseling, as school environments (cafeterias, shared snacks) create constant cross-contamination risk. Growth and nutritional parameters should be monitored carefully, as untreated celiac enteropathy significantly impairs growth velocity.

Reintroduction of oats: Certified gluten-free oats can be cautiously introduced after at least 1–2 years of stable, well-controlled disease on a GFD. Oat reintroduction should be supervised, with clinical reassessment at 6 months. A minority of patients (approximately 5%) experience oat-specific immune reactivity from the avenin protein even with gluten-free oats; these patients should continue to avoid oats permanently.

Back to Table of Contents

Key Research Papers

1. Bolotin D, Petronic-Rosic V. "Dermatitis herpetiformis." J Am Acad Dermatol. 2011;64(6):1017–1024. PMID: 21571168
2. Antiga E, Caproni M. "The diagnosis and treatment of dermatitis herpetiformis." Clin Cosmet Investig Dermatol. 2015;8:257–265. PMID: 25999753
3. Reunala T, Salmi TT, Hervonen K, et al. "Dermatitis Herpetiformis: A Common Extraintestinal Manifestation of Coeliac Disease." Nutrients. 2018;10(5):602. PMID: 29757999
4. Salmi TT, Hervonen K, Kautiainen H, et al. "Prevalence and incidence of dermatitis herpetiformis: a 40-year prospective study." Br J Dermatol. 2011;165(2):354–359. PMID: 21517799
5. Zone JJ. "Skin manifestations of celiac disease." Gastroenterology. 2005;128(4 Suppl 1):S87–91. PMID: 15825132
6. Caproni M, Antiga E, Melani L, et al. "Guidelines for the diagnosis and treatment of dermatitis herpetiformis." J Eur Acad Dermatol Venereol. 2009;23(6):633–638. PMID: 19470076
7. Hervonen K, Hakanen M, Kaukinen K, et al. "First-degree relatives are frequently affected in coeliac disease and dermatitis herpetiformis." Scand J Gastroenterol. 2002;37(1):51–55. PMID: 11843036
8. Reunala T, Collin P, Holm K, et al. "Tolerance to oats in dermatitis herpetiformis." Gut. 1998;43(4):490–493. PMID: 9824575
9. Sugai E, Vazquez H, Nachman F, et al. "Accuracy of testing for antibodies to synthetic gliadin-related peptides in celiac disease." Clin Gastroenterol Hepatol. 2006;4(9):1112–1117. PMID: 16979951
10. Fry L, Seah PP, Harper PG, et al. "The small intestine in dermatitis herpetiformis." J Clin Pathol. 1974;27(10):817–824. PMID: 4375080
11. Collin P, Reunala T, Rasmussen M, et al. "High incidence and prevalence of adult coeliac disease. Augmented diagnostic approach." Scand J Gastroenterol. 1997;32(11):1129–1133. PMID: 9399398
12. Sárdy M, Kárpáti S, Merkl B, et al. "Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis." J Exp Med. 2002;195(6):747–757. PMID: 11901200

Back to Table of Contents

Related PubMed Searches

1. Dermatitis herpetiformis treatment
2. Dermatitis herpetiformis dapsone gluten-free diet
3. Dermatitis herpetiformis IgA direct immunofluorescence diagnosis
4. Epidermal transglutaminase TG3 dermatitis herpetiformis
5. Celiac disease skin manifestations autoimmune

Back to Table of Contents

Featured Videos

Dermatology — Dermatitis herpetiformis overview.

Dermatology — Gluten-IgA mechanism explained.

Celiac Disease — Skin manifestations of celiac disease.

Gastroenterology — Gluten-free diet for DH and celiac disease.

Dermatology — Direct immunofluorescence diagnosis of DH.

Dermatology — Dapsone therapy for blistering skin diseases.

Autoimmune — Celiac disease pathophysiology and HLA-DQ2.

Nutrition — Living on a strict gluten-free diet.

Dermatology — Subepidermal blistering diseases compared.

Gastroenterology — Villous atrophy and intestinal biopsy.

Immunology — IgA deposits and complement activation in skin.

Dermatology — Linear IgA bullous dermatosis vs dermatitis herpetiformis.

Endocrinology — Hashimoto's thyroiditis and celiac disease connection.

Patient — Living with dermatitis herpetiformis and celiac disease.

Dermatology — Autoimmune blistering disease diagnosis and management.

Nutrition — Gluten cross-contamination avoidance for celiac and DH.

Back to Table of Contents

Connections

• Celiac Disease
• Epidermolysis Bullosa
• Pemphigoid Gestationis
• Linear IgA Bullous Dermatosis
• Hashimoto's Thyroiditis
• Gastroenterology

Back to Table of Contents